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The association between passive cigarette smoke exposure and breast cancer risk is inconclusive and may be modified by genotype. The authors investigated lifetime passive cigarette smoke exposures, 36 variants in 12 carcinogen-metabolizing genes, and breast cancer risk among Ontario, Canada, women who had never smoked (2003) (2004) . DNA (saliva) was available for 920 breast cancer cases and 960 controls. Detailed information about passive smoke exposure was collected for multiple age periods (childhood, teenage years, and adulthood) and environments (home, work, and social). Adjusted odds ratios and 95% confidence intervals were estimated by multivariable logistic regression, and statistical interactions were assessed using the likelihood ratio test. Among postmenopausal women, most associations between passive smoke and breast cancer risk were null, whereas among premenopausal women, nonsignificant positive associations were observed. Significant interactions were observed between certain types of passive smoke exposure and genetic variants in CYP2E1, NAT2, and UGT1A7. While these interactions were statistically significant, the magnitudes of the effect estimates were not consistent or easily interpretable, suggesting that they were perhaps due to chance. Although the results of this study were largely null, it is possible that premenopausal women exposed to passive smoke or carrying certain genetic variants may be at higher risk of breast cancer. breast neoplasms; single nucleotide polymorphisms; tobacco smoke pollution Abbreviations: AOR, age-adjusted odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.
Cigarette smoking is causally associated with 10 types of cancer (1) ; however, the association between smoking and breast cancer is unclear (2) (3) (4) . Passive exposure to cigarette smoke has been associated with increased breast cancer risk in several reviews, particularly among premenopausal women (5) (6) (7) (8) (9) , but this conclusion is not universally supported (10) (11) (12) . Despite the inconclusive results of epidemiologic studies, there are multiple biologic mechanisms through which tobacco smoke exposure could induce breast cancer (3) , and sidestream tobacco smoke exposure may be worse than mainstream exposure (5, 9) .
Genetic variation may modify the association between smoke exposure and breast cancer risk. More than 50 studies have evaluated the association between active smoking and breast cancer risk by genotype (as reviewed by Terry and Goodman (13) ), while fewer gene-environment studies have evaluated passive smoke exposure. Commonly studied genes include those for enzymes involved in the metabolism of tobacco carcinogens (e.g., cytochrome P-450 1A1 (CYP1A1), cytochrome P-450 1B1 (CYP1B1), glutathione S-transferase M1 (GSTM1), glutathione S-transferase T1 (GSTT1), N-acetyltransferase 2 (NAT2), and sulfotransferase 1A1 (SULT1A1)) or oxidative metabolism (e.g., superoxide dismutase 2 (SOD2)) (13) . Most studies that have examined genetic modification of the association between passive smoke exposure and breast cancer risk have evaluated only the NAT2 genotype (14) (15) (16) (17) (18) (19) (20) (21) , with conflicting results. Few studies have evaluated other genetic variants (20, (22) (23) (24) (25) (26) .
The objectives of the current study were to evaluate the association between passive smoke exposure and breast cancer risk among pre-and postmenopausal women during childhood, the teenage years, and adulthood and possible interactions with variants in carcinogen-metabolizing genes. The analysis was conducted among never-smoking women in a population-based case-control study of breast cancer in Ontario, Canada.
MATERIALS AND METHODS

Study design and subject recruitment
This study utilized data from women who participated in the Ontario Women's Diet and Health Study, a large population-based case-control study in Ontario, Canada, that has been previously described (27, 28) . Briefly, 3,101 cases were identified from the Ontario Cancer Registry between 2002 and 2003, and 3,471 controls (frequency agematched 1:1) were identified through random digit dialing of Ontario households. The University of Toronto Research Ethics Board granted ethics approval for this study.
Data collection
From 2003 to 2004, all study participants completed a mailed food frequency questionnaire and a detailed risk factor questionnaire collecting information on known breast cancer risk factors, other potential covariates, and willingness to provide a saliva sample (DNA) at some future time. In 2007, cases and controls who had agreed to provide saliva were mailed a 2-page secondhand smoke questionnaire (data on active smoking were collected in the original questionnaire) and an Oragene kit (DNA Genotek, Inc., Ottawa, Ontario, Canada) for saliva collection, along with instructions and a consent form. The signed consent form and Oragene kit were returned by courier to the Biospecimen Repository at Mount Sinai Hospital (Toronto, Ontario).
Response rate/numbers
The study enrolled 3,101 breast cancer cases and 3,471 controls; among these, 2,563 cases (83%) and 2,567 controls (74%), respectively, indicated that they were willing to provide a biologic sample for DNA in the future. Study packages were mailed to 2,466 cases and 2,515 controls; 50 women requested no further contact, 39 were no longer alive, and 95 had moved (addresses unavailable). Completed questionnaires and saliva samples were returned by 1,776 cases (72%) and 1,839 controls (73%), and DNA was isolated for a total of 3,503 participants (<60% of participants in the Ontario Women's Diet and Health Study). Women who provided DNA were compared with those who did not; they were found to be less likely to be current smokers and more likely to have a higher income and be Caucasian. Age and body mass index were similar between the two groups (data not shown).
Passive smoke variables
The passive smoke questionnaire asked about ''possible exposure to the tobacco smoke of others during various age periods of your life'' in 3 settings: home, workplace, and social (nonwork, nonhome) environments, and during 6 age periods of exposure: childhood (ages 2-12 years), the teenage years (13-19 years) , the 20s (ages 20-29 years), the 30s (ages 30-39 years), the 40s (ages 40-49 years), and the 50s and above (age !50 years). For each setting, study participants were asked, ''During each age period, were you ever exposed to the tobacco smoke of others?'' (yes or no). If the response was yes, information on the duration of exposure was collected by asking, ''How many years during each age period?'' (<1, 1-3, 4-6, or 7-9 years). The frequencies of exposure at home and at work during each age period were assessed by asking, ''How many hours a day on average were you exposed to the tobacco smoke of others?'' ( 2, 3-6, or !7 hours), and for exposure in social environments, ''How many hours a week on average?'' ( 2, 3-6, or !7 hours).
Women were classified as ''only passive'' if they reported never smoking more than 100 cigarettes during their lifetimes but reported having been exposed to tobacco smoke from a household member during childhood or having been exposed to the tobacco smoke of others as a teen or adult at home, at work, or socially (for !2 hours/week). Active (ever or current) smokers were excluded from all analyses to minimize misclassification. Passive smoke variables included hours of exposure incurred as a child, a teen, and an adult (cumulative over the ages 20s, 30s, 40s, and !50 years) at home, at work, and in social environments (calculated as average number of hours per day 3 365.25 days/year 3 total number of years exposed for each age group and environment). The referent group for all passive smoke variables was restricted to ''never active and never passive smokers.'' Passive smoke exposure variables were categorized on the basis of the distribution among controls. We also examined passive smoke exposure in relation to pregnancy exposure: only before the first pregnancy, only after the first pregnancy, or both before and after the first pregnancy.
DNA preparation and genotyping DNA was isolated from saliva samples using Buccal Amp DNA extraction kits (Epicenter Biotechnologies, Madison, Wisconsin) and stored at À80°C. Genetic variants (with at least 5% prevalence) in genes within relevant metabolic pathways, including some polymorphisms previously found to be associated with cancer risk, were selected. Genotyping was conducted on 36 single nucleotide polymorphisms (SNPs) in 12 candidate genes: CYP1A1, CYP1A2, CYP1B1, CYP2E1, EPHX1 (epoxide hydrolase 1), NAT1, NAT2, UGT1A7 (uridine diphosphate glucuronosyltransferase 1A7), SOD2, SULT1A1, GSTM1, and GSTT1. With the exception of GSTM1 and GSTT1 variants, all of the genotyping was carried out using the MassARRAY iPLEX Gold Sequenom Platform (Sequenom, San Diego, California; www.sequenom. com) offered at the University Health Network Analytical Genetics Technology Centre (Toronto). A previously published multiplex polymerase chain reaction protocol was used for analysis of the GSTM1 and GSTT1 polymorphisms (29) . Known genotype control samples were included in each polymerase chain reaction plate, and reproducibility was assured by making sure that control sample results were consistent across the different plates analyzed. Furthermore, 5% of samples were randomly selected for blinded duplicate analysis. The SNP call rate was greater than 99%.
Statistical data analysis
The association between each passive smoke variable and breast cancer was evaluated using logistic regression to estimate age-adjusted odds ratios and 95% confidence intervals. Analysis of passive smoke variables was restricted to women who had never smoked and was stratified by menopausal status.
Confounding of the association between passive smoke and breast cancer risk was evaluated by examining whether the age-adjusted odds ratio for the smoke variables changed by more than 10% between models with and without each covariate (30) . Potential confounders included age at menarche, age at first livebirth, parity, age at menopause, oral contraceptive use, hormone/estrogen replacement therapy, benign breast disease, family history of breast cancer, ethnicity, education, mammography, body mass index, dietary fat, alcohol intake, and physical activity (daily, moderate, and strenuous activity during multiple age periods). No confounders were identified in the postmenopausal strata, and only type of physical activity during the teens was identified as a confounder in the premenopausal strata.
All analyses were performed using SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina), with the exception that candidate biallelic SNPs were tested for departures from Hardy-Weinberg equilibrium among controls only using the R package ''Genetics'' (31). Significant departure from Hardy-Weinberg equilibrium (P < 0.05) was detected for 4 SNPs: NAT1 c.640T>G (rs49867830; P ¼ 0.015), NAT2 c.-6-1799A>G (rs1961456; P ¼ 0.010), CYP2E1 c.826-333C>A (rs915907; P ¼ 0.011), and SULT1A1 c.638G>A (rs9282861; P ¼ 0.002).
Composite genotypes were derived for NAT1, NAT2, and UGT1A7 genes on the basis of known phenotypes of single SNP combinations. All genetic polymorphisms were tested for an association with breast cancer using age-adjusted logistic regression analysis in the overall sample and by menopausal status. Because of low heterozygosity, NAT2 c.191G>A (rs1801279) was excluded from further analyses. Each of the remaining 35 genetic variants was separately assessed for interaction with passive smoke. Rare homozygous genotypes with frequencies below 5% were combined with the heterozygotes if the estimated age-adjusted odds ratios pointed in the same direction, and otherwise were discarded. The interaction between each passive smoke variable and genetic polymorphism was formally assessed by means of a likelihood ratio test comparing the models with and without the product term (significance was defined as P < 0.05). For all statistically significant interactions, analyses stratified by genotype were performed to obtain odds ratio estimates of association between breast cancer and the smoke variables among pre-and postmenopausal women.
RESULTS
The analysis was based on 920 breast cancer cases and 960 controls who had never smoked. Passive smoke exposures were not associated with overall breast cancer risk among pre-and postmenopausal women combined (data not shown); stratified results are presented, since odds ratios differed by menopausal status. Table 1 shows the distributions of breast cancer cases and controls according to selected descriptive characteristics, established breast cancer risk factors, and passive smoke exposure variables. No significant associations between hours of passive smoke exposure and breast cancer risk were observed (Table 1) . Among premenopausal women only, odds ratios greater than 1.0 were consistently observed for the highest categories of hours of adult passive smoke exposure in all environments, but results were not statistically significant. In relation to timing of pregnancy, a reduced risk of breast cancer was observed among postmenopausal women exposed only before the first pregnancy (age-adjusted odds ratio (AOR) ¼ 0.51, 95% confidence interval (CI): 0.29, 0.89); all other associations were null (data not shown). Table 3 shows associations between passive smoke exposure variables and breast cancer risk by genotype for all statistically significant interactions (P < 0.05) among preand postmenopausal women. All other tests for interaction were not statistically significant at the nominal 5% testing level; the P values for all interactions between adult passive smoke exposure (cumulative over all environments) and each SNP ranged from 0.09 to 0.95 among premenopausal women and from 0.12 to 0.97 among postmenopausal women. Among premenopausal women, significant interactions were observed between passive smoke exposure during certain age periods and 3 genetic variants in NAT2 and UGT1A7. Among postmenopausal women, significant interactions were observed only between CYP2E1 and NAT2 genotypes and passive smoke exposure during the teenage years ( Table 3 ). The few significant odds ratios revealed in stratified analyses by genotype were not always consistent with the hypothesis of increased risk among women with certain genotypes. For example, although increased breast cancer risk was observed among premenopausal women with the UGT1A7 c.855þ44947-GG genotype exposed to passive smoke at work as an adult (AOR ¼ 6.33, 95% CI: 1.69, 23.71), the GT genotype was associated with reduced breast cancer risk (AOR ¼ 0.34, 95% CI: 0.12, 0.94).
DISCUSSION
In this population-based case-control study, we comprehensively evaluated lifetime passive smoke exposure in relation to pre-and postmenopausal breast cancer risk among never smokers. After thorough assessment of passive smoke exposure (including multiple environments and age periods), there was limited evidence to suggest that passive smoke exposure is associated with increased breast cancer risk. Nonsignificant associations in the direction of increased risk were observed in the highest categories of adult passive smoke exposure in premenopausal women only. This is somewhat consistent with several reviews that suggested an increased risk predominantly among premenopausal women (5, 7, 8) , possibly due to differences in tumor histology and estrogen receptor status (8) . Although several groups of investigators have reported an increased risk (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) , many findings have been null (12, (43) (44) (45) (46) (47) (48) , and case-control studies have been more likely than cohort studies to find an association (8, 12) . The potential for recall bias has raised questions regarding the validity of the former (12) , and measurement error due to incomplete exposure assessment is a possible explanation for the null findings among the latter (3, 7, 8) . Investigators in the California Teachers Study, a large cohort study, first reported no association between household passive smoke exposure and breast cancer (45); however, after more detailed data were collected, new results suggested increased risk among postmenopausal women (32) .
We assessed many variants in candidate genes known to be involved in the metabolism/activation of tobacco smoke. The biologic function of these genes in altering carcinogenmetabolizing enzymes has been reviewed elsewhere (13, 49) . Only 5 of the 114 odds ratios presented in Table 2 were statistically significant, as would be expected by chance alone. Independently of passive smoke exposure, breast cancer risk was increased among premenopausal women with CYP2E1 c.826-333-CA and CYP2E1 c.967þ1143-AA/ AT genotypes and postmenopausal women with CYP1A1 3801-CC and CYP1A2 c.-9-1548-CC genotypes, and was decreased among postmenopausal women with the SULT1A1 c.638-AG genotype; however, 2 of these significant SNPs were not in Hardy-Weinberg equilibrium (CYP2E1 c.826-333C>A and SULT1A1 c.638G>A). It is unclear why 4 SNPs in our study demonstrated significant departure from Hardy-Weinberg equilibrium. Genotyping quality did not appear to be a concern; thus, these departures may have been due to population admixture or chance. Among both pre-and postmenopausal women, few significant gene-environment interactions were observed, and these may be explained by chance alone. Some significant associations were observed 2 . e Hours of passive smoke exposure were calculated as the average number of hours of exposure per day 3 365.25 days/year 3 total number of years exposed for each age group (childhood, teenage years, adulthood (ages !20 years)) and environment (home, work, social) and then summed over the indicated age group and environment.
f Cumulative passive smoke exposure in home, work, and social environments during the teenage years (ages 13-19 years). g Cumulative passive smoke exposure in adulthood (ages !20 years). h Cumulative passive smoke exposure in home, work, and social environments in adulthood (ages !20 years).
within specific strata of CYP2E1, NAT2, and UGT1A7 variants. N-acetyltransferase enzymes activate tobacco carcinogens, and the relations between variants in NAT2 (associated with a slow acetylator phenotype), passive smoke exposure, and breast cancer risk have received the most previous attention. Consistent with our results, NAT1 or NAT2 genotypes have generally not been associated with breast cancer risk independently of smoke exposure (20, (50) (51) (52) . Polymorphisms in NAT2 modify the association between passive smoke exposure and breast cancer risk in some (14) (15) (16) (19) (20) (21) but not all (17, 18) studies. However, investigators have reported inconsistent results regarding whether the association between passive smoke and breast cancer is stronger among fast (16, (19) (20) (21) or slow (14, 15) NAT2 acetylators. We observed significant interactions between selected NAT2 SNPs and passive smoke exposure during the teenage years, but after stratification by genotype, most of the associations with breast cancer risk were not significant. For NAT1, Millikan et al. (20) reported that 4 variants did not modify the association between environmental exposure to tobacco smoke and breast cancer risk, and we did not find any significant interactions between NAT1 variants and passive smoke exposure. The previous studies were limited by small sample Table continues sizes (i.e., <500 cases) (14) (15) (16) (17) (19) (20) (21) or measured only passive smoke exposure from a spouse or other household members (14, 17, 20) . Cytochrome P-450 enzymes bioactivate cigarette smoke carcinogens. Despite recent meta-analyses suggesting that this SNP is not associated with breast cancer risk (53-55), we found that the CYP1A1 3801T>C polymorphism was associated with increased postmenopausal breast cancer risk; however, no significant interactions with passive smoke exposure variables were observed. In contrast, in a 2004 study, Li et al. (24) reported that the association between living with a smoker and premenopausal breast cancer risk was increased among women with the CYP1A1 3801T>C polymorphism.
For the CYP1B1 c.1294G>C polymorphism, we did not find any significant interactions. Elsewhere, a non-statistically significant increased breast cancer risk among passive smokers has been reported for this polymorphism (22) , while in a small case-only study, this variant was associated with breast cancer among current smokers but not among passive smokers (56) . To our knowledge, we are the first to report increased pre-and postmenopausal breast cancer risk with CYP2E1 c.826-333 C>A and CYP1A2 c.1548 T>C, respectively, and a significant interaction between one CYP2E1 polymorphism and teenage passive smoke exposure. Since there are no other reports on these associations, future studies are needed to replicate or refute these findings. Table continues SULT1A1 is involved in the bioactivation of procarcinogens (57) . We found that the SULT1A1 c.638 G>A polymorphism was inversely associated with postmenopausal breast cancer risk; however, this SNP was not in Hardy-Weinberg equilibrium in our study population, and previous meta-analyses suggested that this SNP is associated with increased breast cancer risk among Asian women only (58, 59) . Consistent with one previous study (23), we did not observe any significant interactions between this SULT1A1 polymorphism, passive smoke exposure, and breast cancer risk. To our knowledge, this paper is the first to describe the association between passive smoke exposure, breast cancer risk, and variants in the EPHX1, SOD2, UGT1A7, GSTM1, and GSTT1 genes. We did not find any associations between these genetic variants and pre-or postmenopausal breast cancer risk, and significant interactions were only observed between adult passive smoke exposure variables and the UGT1A7 c.855þ 44947T>G polymorphism.
The association between passive smoke exposure and breast cancer risk may depend upon the timing of exposure. Breast cells are potentially more susceptible to carcinogens during the childhood/teenage years or before the first pregnancy, Table continues prior to cell differentiation (36, 60) . Some previous studies found positive associations between passive smoke exposure during childhood and breast cancer risk (36, 38) but, consistent with our overall results, most studies of early life exposure have not found significant associations (7, 12, 32, 34, 37, 39, 46, 61) . However, we cannot rule out the possibility that increased reporting error for early life exposures drove the findings towards the null. A few significant interactions were observed between genetic variants and passive smoke exposure during adolescence. Unexpectedly, we found significant inverse associations for passive smoke exposure during the teenage years among premenopausal women with the NAT2 c.341CC and NAT2 c.803-GG genotypes and among postmenopausal women with CYP2E1 c.1298-208-CT/TT genotypes. In previous studies of passive smoke exposure during childhood or the teenage years, researchers have not reported significant inverse associations (7, 12, 32) , even after considering genetic differences (16, 19) . Tobacco smoke may have antiestrogenic effects and has been linked with factors associated with reduced breast cancer risk, such as earlier age at menopause and lower body mass index (9) . However, as reviewed elsewhere, circulating estrogen levels have not been found to differ between smokers and nonsmokers (2) , and the many harmful health effects from tobacco smoke carcinogens likely outweigh any potential antiestrogen activity. Our study is one of the largest to report on lifetime passive smoke exposure, genetic variants, and breast cancer risk. It is still possible, however, that significant interactions were not detected because of lack of power. Conversely, multiple testing is always a concern, and although all SNPs were selected a priori based on suspected function using a candidate gene approach, we are unable to rule out the possibility that some findings may have been due to chance. Misclassification is a potential limitation of all observational studies, and many previous studies defined passive smoke exposure only as living with a smoker (14, 17, 24, 62, 63) , whereas our study was one of the few to comprehensively assess smoke exposure in multiple environments and during multiple age periods of life. Approximately 60% of cases and controls provided saliva (DNA) and completed the supplementary passive smoke exposure questionnaire, and these women were slightly different from nonparticipants with regard to some characteristics, but it is unlikely that this would have biased our results regarding genotypes and breast cancer risk. We were able to assess the association between passive smoke exposure and breast cancer risk among all women participating in the Ontario Women's Diet and Health Study (3,101 cases and 3,471 controls), using 2 relatively crude passive smoke questions included in the first Ontario Women's Diet and Health Study questionnaire. Similar to our results among women with DNA, no association was observed overall. Survival bias is unlikely, since breast cancer survival is very high, with a 5-year relative survival ratio of 87% (64) .
We present results from one of the most comprehensive studies in this area to have been carried out thus far, with detailed estimates of passive smoke exposure, assessment of a range of genetic variants, and a relatively large sample size. The biologic plausibility of an association between passive smoke exposure and breast cancer risk is high. It has been argued that an association between passive smoke and breast cancer risk is implausible in the absence of an association with active smoking; however, sidestream smoke contains a higher ratio of carcinogens and toxic chemicals than mainstream smoke, and thus passive smoke exposure may be worse (5, 9) . Therefore, although our study results were largely null, we cannot rule out the possibility that an increased breast cancer risk is present in premenopausal women exposed to passive smoke or specific subgroups of the population based on genetic variation in certain carcinogenmetabolizing genes.
